Bristol Myers says FDA accepts sNDA for KRAZATI in combination with cetuximab

Bristol Myers Squibb announced that the U.S. FDA has accepted for priority review the supplemental new drug application for KRAZATI in combination with cetuximab for the treatment of patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer. The FDA assigned a Prescription Drug User Fee Act goal date of June 21, 2024.